Reversion of multidrug resistance by a pH-responsive cyclodextrin-derived nanomedicine in drug resistant cancer cells

Biomaterials

Volumn 67, Issue , 2015, Pages 169-182

  Shi, Qing ^a   Zhang, Lin ^a   Liu, Mengyu ^a   Zhang, Xuelin ^a   Zhang, Xiangjun ^a   Xu, Xiaoqiu ^a   Chen, Sha ^a   Li, Xiaohui ^a   Zhang, Jianxiang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cyclodextrin; Drug delivery; Multidrug resistance; Nanomedicine; Pgp inhibitor; PH responsive

Indexed keywords

CELL DEATH; CELL MEMBRANES; CELL PROLIFERATION; CHEMOTHERAPY; CYCLODEXTRINS; DISEASES; DRUG DELIVERY; DRUG PRODUCTS; MEDICAL NANOTECHNOLOGY; MITOCHONDRIA; TARGETED DRUG DELIVERY;

CHEMOTHERAPEUTIC AGENTS; INNOVATIVE STRATEGIES; INTRACELLULAR DELIVERY; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIDRUG RESISTANCE; PGP INHIBITOR; PH-RESPONSIVE; SUBCELLULAR ORGANELLES;

CONTROLLED DRUG DELIVERY;

ADENOSINE TRIPHOSPHATASE; ALPHA CYCLODEXTRIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; NANOCARRIER; PACLITAXEL; VERAPAMIL; ALPHA CYCLODEXTRIN DERIVATIVE; ALPHA-CYCLODEXTRIN; NANOPARTICLE; RHODAMINE 123;

ACTIN FILAMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER CHEMOTHERAPY; CELL DENSITY; CONTROLLED STUDY; CYTOSKELETON; ENDOCYTOSIS; HUMAN; HUMAN CELL; IC50; INTERNALIZATION; JAPAN; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIDRUG RESISTANCE; NANOFABRICATION; NANOMEDICINE; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; ACETYLATION; APOPTOSIS; CELL CYCLE; CELL MEMBRANE; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; ENERGY METABOLISM; METABOLISM; NEOPLASMS; PATHOLOGY; PH; TUMOR CELL LINE; ULTRASTRUCTURE;

ACETYLATION; ADENOSINE TRIPHOSPHATASES; ALPHA-CYCLODEXTRINS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL MEMBRANE; CYTOSKELETON; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; ENERGY METABOLISM; HUMANS; HYDROGEN-ION CONCENTRATION; MEMBRANE POTENTIAL, MITOCHONDRIAL; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; RHODAMINE 123;

EID: 84939627623     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.07.023     Document Type: Article

References (55)

1. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2:48-58.
2. Fellner S., Bauer B., Miller D.S., Schaffrik M., Fankhänel M., Spruss T., et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Invest. 2002, 110:1309-1318.
3. Dong X., Mattingly C.A., Tseng M.T., Cho M.J., Liu Y., Adams V.R., et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res. 2009, 69:3918-3926.
4. Cho K., Wang X., Nie S., Chen Z.G., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008, 14:1310-1316.
5. Batrakova E.V., Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control Release 2008, 130:98-106.
6. Kunjachan S., Rychlik B., Storm G., Kiessling F., Lammers T. Multidrug resistance: physiological principles and nanomedical solutions. Adv. Drug Deliv. Rev. 2013, 65:1852-1865.
7. Minko T., Rodriguez-Rodriguez L., Pozharov V. Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv. Drug Deliv. Rev. 2013, 65:1880-1895.
8. Livney Y.D., Assarafc Y.G. Rationally designed nanovehicles to overcome cancer chemoresistance. Adv. Drug Deliv. Rev. 2013, 65:1716-1730.
9. Dong X., Mumper R.J. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine 2010, 5:597-615.
10. Markman J.L., Rekechenetskiy A., Holler E., Ljubimova J.Y. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv. Drug Deliv. Rev. 2013, 65:1866-1879.
11. Alakhova D.Y., Kabanov A.V. Pluronics and MDR reversal: an update. Mol. Pharmacol. 2014, 11:2566-2578.
12. Kievit F.M., Wang F.Y., Fang C., Mok H., Wang K., Silber J.R., et al. Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J. Control Release 2011, 152:76-83.
13. Arora H.C., Jensen M.P., Yuan Y., Wu A., Vogt S., Paunesku T., et al. Nanocarriers enhance doxorubicin uptake in drug-resistant ovarian cancer cells. Cancer Res. 2012, 72:769-778.
14. Nieto Montesinos R., Béduneau A., Pellequer Y., Lamprecht A. Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes. J. Control Release 2012, 161:50-61.
15. Soma C.E., Dubernet C., Bentolila D., Benita S., Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 2008, 21:1-7.
16. Patil Y., Sadhukha T., Ma L., Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control Release 2009, 136:21-29.
17. Xiong X.B., Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 2011, 5:5202-5213.
18. Gandhi N.S., Tekade R.K., Chougule M.B. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J. Control Release 2014, 194:238-256.
19. Zhang J.X., Jia Y., Li X.D., Hu Y.Q., Li X.H. Facile engineering of biocompatible materials with pH-modulated degradability. Adv. Mater 2011, 23:3035-3040.
20. Chen H.P., Liu X.P., Dou Y., He B.F., Liu L., Wei Z.H., et al. A pH-responsive cyclodextrin-based hybrid nanosystem as a nonviral vector for gene delivery. Biomaterials 2013, 34:4159-4172.
21. He H.M., Chen S., Zhou J.Z., Dou Y., Song L., Che L., et al. Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel. Biomaterials 2013, 34:5344-5358.
22. Liu X.P., Wang G.S., You Z.C., Qian P., Chen H.P., Dou Y., et al. Inhibition of hypoxia-induced proliferation of pulmonary arterial smooth muscle cells by a mTOR siRNA-loaded cyclodextrin nanovector. Biomaterials 2014, 35:4401-4416.
23. Zhang D.L., Wei Y.L., Chen K., Gong H., Han S.L., Guo J.W., et al. Engineering of biocompatible pH-responsive nanovehicles from acetalated cyclodextrins as effective delivery systems for tumor therapy. J. Biomed. Nanotechnol. 2015, 11:923-941.
24. Arima H., Yunomae K., Hirayama F., Uekama K. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus. J. Pharmacol. Exp. Ther. 2001, 297:547-555.
25. Petriz J., Garcia-Lopez J. Flow cytometric analysis of P-glycoprotein function using rhodamine 123. Leukemia 1997, 11:1124-1130.
26. Batrakova E.V., Li S., Vinogradov S.V., Alakhov V.Y., Miller D.W., Kabanov A.V. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther. 2001, 299:483-493.
27. Hamada H. Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988, 48:4926-4932.
28. Byun H.S., Song J.K., Kim Y.R., Piao L., Won M., Park K.A., et al. Caspase-8 has an essential role in resveratrol-induced apoptosis of rheumatoid fibroblast-like synoviocytes. Rheumatology 2007, 47:301-308.
29. Chuang H.C., Jones T., Chen T.T., BéruBé K. Cytotoxic effects of incense particles in relation to oxidative stress, the cell cycle and F-actin assembly. Toxicol. Lett. 2013, 220:229-237.
30. Khalil I.A., Kogure K., Akita H., Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol. Rev. 2006, 58:32-45.
31. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. J. Control Release 2010, 145:182-195.
32. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
33. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6:688-701.
34. Bertrand N., Wu J., Xu X., Kamaly N., Farokhzad O.C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 2014, 66:2-25.
35. Torchilin V.P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug Discov. 2014, 13:813-827.
36. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7:771-782.
37. Patel N.R., Pattni B.S., Abouzeid A.H., Torchilin V.P. Nanopreparations to overcome multidrug resistance in cancer. Adv. Drug Deliv. Rev. 2013, 65:1748-1762.
38. Peetla C., Vijayaraghavalu S., Labhasetwar V. Biophysics of cell membrane lipids in cancer drug resistance: implications for drug transport and drug delivery with nanoparticles. Adv. Drug Deliv. Rev. 2013, 65:1686-1698.
39. Davis M.E., Brewster M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov. 2004, 3:1023-1035.
40. Zhang J.X., Ma P.X. Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective. Adv. Drug Deliv. Rev. 2013, 65:1215-1233.
41. Li J., Loh X.J. Cyclodextrin-based supramolecular architectures: syntheses, structures, and applications for drug and gene delivery. Adv. Drug Deliv. Rev. 2008, 60:1000-1017.
42. Davis M.E. Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv. Drug Deliv. Rev. 2009, 61:1189-1192.
43. Davis M.E., Zuckerman J.E., Choi C.H.J., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
44. Zhang J.X., Ma P.X. Host-guest interactions mediated nanoassemblies using cyclodextrin-containing hydrophilic polymers and their biomedical applications. Nano Today 2010, 5:337-350.
45. DiMauro S., Schon E.A. Mitochondrial respiratory-chain diseases. N. Engl. J. Med. 2003, 348:2656-2668.
46. Sharom F.J., Yu X., Chu J.W., Doige C.A. Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochem. J. 1995, 308:381-390.
47. Batrakova E.V., Li S., Li Y., Alakhov V.Y., Kabanov A.V. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm. Res. 2004, 21:2226-2233.
48. Batrakova E.V., Li S., Elmquist W.F., Miller D.W., Alakhov V.Y., Kabanov A.V. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br. J. Cancer 2001, 85:1987-1997.
49. Lalloo AKL F.R., Guo A., Paranjpe P.V., Lee S.H., Vyas V., Rubin E., et al. Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2). BMC Med. 2004, 2:1-12.
50. Roy A., Murakami M., Ernsting M.J., Hoang B., Undzys E., Li S.D. Carboxymethylcellulose-based and docetaxel-loaded nanoparticles circumvent P-glycoprotein-mediated multidrug resistance. Mol. Pharmacol. 2014, 11:2592-2599.
51. Batrakova E.V., Lee S., Li S., Venne A., Alakhov V.Y., Kabanov A.V. Fundamental relationships between the composition of Pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. 1999, 16:1373-1379.
52. Montesinos N.R., Béduneau A., Pellequer Y., Lamprecht A. Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes. J. Control Release 2012, 161:50-61.
53. Pajatsch M., Gerhart M., Peist R., Horlacher R., Boos W., Böck A. The periplasmic cyclodextrin binding protein CymE from Klebsiella oxytoca and its role in maltodextrin and cyclodextrin transport. J. Bacteriol. 1998, 180:2630-2635.
54. Grosse P.Y., Bressolle F., Pinguet F. Methyl-beta-cyclodextrin in HL-60 parental and multidrug-resistant cancer cell lines: effect on the cytotoxic activity and intracellular accumulation of doxorubicin. Cancer Chemother. Pharmacol. 1997, 40:489-494.
55. Yunomae K., Arima H., Hirayama F., Uekama K. Involvement of cholesterol in the inhibitory effect of dimethyl-beta-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. FEBS Lett. 2003, 536:225-231.